文献速递妇科

肿瘤相关巨噬细胞在卵巢癌中的预后意义:一项Meta分析

Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis.
PubMed 文献 · Gynecol Oncol · 2017-07-08

该Meta分析纳入9项研究共794例卵巢癌患者,评估肿瘤相关巨噬细胞(TAM)亚群与预后的相关性。结果显示肿瘤组织中M1/M2比值高与总生存期(OS)改善相关(HR=0.449,95%CI=0.283-0.712,P=0.001),CD163+ TAM高密度与无进展生存期(PFS)较差相关(HR=2.157,95%CI=1.406-3.312,P=0.000)。结论认为CD163+ TAM浸润与卵巢癌不良预后相关,而M1/M2比值高预示较好预后。

要点

  • 肿瘤组织M1/M2 TAMs比值高与OS改善相关(HR=0.449,95%CI=0.283-0.712,P=0.001)。
  • CD163+ TAMs高密度与PFS较差相关(HR=2.157,95%CI=1.406-3.312,P=0.000)。
  • CD68+ TAMs、CD163+ TAMs及CD163+/CD68+比值与OS无显著相关。

核心结论

  • CD163+ TAMs浸润与卵巢癌不良预后相关,肿瘤组织中M1/M2巨噬细胞比值高预示较好预后。

研究设计与样本

  • Meta分析,系统检索PUBMED/Medline和EMBASE数据库,纳入9项研究共794例卵巢癌患者,采用随机效应模型计算HR及95%CI,并进行敏感性分析和Begg检验。

主要发现

  • 肿瘤组织M1/M2比值高与OS改善相关(HR=0.449,95%CI=0.283-0.712,P=0.001)。
  • 胰岛内M1/M2 TAMs比值升高与OS正相关(HR=0.510,95%CI=0.264-0.986,P=0.045)。
  • OS与CD68+ TAMs(HR=0.99,95%CI=0.88-1.11,P=0.859)、CD163+ TAMs(HR=1.04,95%CI=0.92-1.16,P=0.544)及CD163+/CD68+ TAMs比值(HR=1.628,95%CI=0.529-5.008,P=0.395)无显著相关。
  • CD163+ TAMs高密度与PFS较差相关(HR=2.157,95%CI=1.406-3.312,P=0.000),CD163+/CD68+ TAMs比值高与PFS较差相关(HR=3.223,95%CI=1.805-5.755,P=0.000)。
  • M1/M2 TAMs比值升高预示卵巢癌PFS较好(HR=0.490,95%CI=0.270-0.890,P=0.019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of tumor-associated macrophages (TAMs) in tumor microenvironment remains controversial due to the two different polarized subsets of TAMs. Here, we performed a meta-analysis to evaluate the correlation between subpopulations of TAMs and clinical outcomes in patients with ovarian cancer. METHODS: A comprehensive search in PUBMED/Medline and EMBASE databases was performed. The association between TAMs and patient prognosis of ovarian cancer was estimated with hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) using a random-effect model. Additionally, sensitivity analysis and Begg's test were conducted. RESULTS: Nine studies including 794 patients were enrolled in the meta-analysis. The results showed that higher M1/M2 ratio in tumor tissues was associated with a favorable overall survival (OS) (HR=0.449, 95% CI=0.283-0.712, P=0.001). Elevated intra-islet M1/M2 TAMs ratio showed a positive correlation for OS (HR=0.510, 95% CI=0.264-0.986, P=0.045). No significant relation was observed between OS and CD68+ TAMs (HR=0.99, 95% CI=0.88-1.11, P=0.859), CD163+ TAMs (HR=1.04, 95% CI=0.92-1.16, P=0.544) or CD163+/CD68+ TAMs ratio (HR=1.628, 95% CI=0.529-5.008, P=0.395). Worse progression-free survival (PFS) was associated with high density of CD163+ TAMs (HR=2.157, 95% CI=1.406-3.312, P=0.000) and higher ratio of CD163+/CD68+ TAMs (HR=3.223, 95% CI=1.805-5.755, P=0.000). Elevated M1/M2 TAMs ratio predicted better PFS of ovarian cancer (HR=0.490, 95% CI=0.270-0.890, P=0.019). Furthermore, high density of CD163+ and CD68+ TAMs was observed in ovarian cancer with advanced TNM stage. CONCLUSION: In our study, it was revealed that CD163+ TAMs infiltration was associated with poor prognosis of ovarian cancer and high M1/M2 macrophages ratio in tumor tissues predicted better prognosis.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Yuan X, Zhang J, Li D, et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017. PMID: 28698008. doi:10.1016/j.ygyno.2017.07.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。